CRVS in the 13F filings
Corvus Pharmaceuticals Inc · CUSIP 221015100
- Quarter end
- 31 Mar 2026
- the date the book describes
- Filed
- 15 May 2026
- latest of these filings; the earliest 12 May 2026
- Managers listing it
- 19
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q4 2025 and Q1 2026; 0 listed it in both
- Shares listed
- 8,635,343
- combined, among listed positions
- Reported value
- $126m
- combined, at the quarter end
AllianceBernstein LP. Values in this filing are at the previous quarter end's prices; its share count is the quarter end's.
Among the 91 comparable managers: 16 buyers (opened or added shares) and 8 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +3,348,844.
Managers listing CRVS in Q1 2026
19 of 19 holders
Largest increases and reductions, by shares
Increases
- T. Rowe Price Associates Incexisting position · 2,917,300 shares now+2,883,195
- Wellington Management Group LLPexisting position · 2,318,517 shares now+2,003,834
- Two Sigma Investments LPexisting position · 539,869 shares now+396,271
- Marshall Wace LLPexisting position · 548,285 shares now+332,037
- Voloridge Investment Management LLCnew position · 278,007 shares now+278,007
Reductions
- Jane Street Group LLCexisting position · 44,473 shares now-333,824
- Susquehanna International Group LLPexisting position · 38,636 shares now-23,118
- Invesco Ltdexisting position · 38,212 shares now-5,371
New positions and exits
New (7)
Exited (5)
- Point72 Asset Management LPwas $22m
- ExodusPoint Capital Management LPwas $668k
- D. E. Shaw & Co.was $500k
- Balyasny Asset Management LLCwas $193k
- Verition Fund Management LLCwas $165k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q1 2017 | 1 | $8.5m | n.a. | n.a. |
| Q4 2022 | 1 | $466k | n.a. | n.a. |
| Q1 2023 | 1 | $499k | n.a. | n.a. |
| Q3 2024 | 1 | $29m | 0 | 1 |
| Q2 2025 | 1 | $28m | 1 | 0 |
| Q3 2025 | 1 | $48m | 0 | 1 |
| Q1 2026 | 1 | $2.5m | 16 | 8 |
| Q2 2026 | 1 | $3.7m | 10 | 11 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
CRVS and LLY →CRVS and JNJ →CRVS and VRTX →Choose a stock to compare with CRVS →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own CRVS, latest filings →Back to the 13F Explorer →